Lucentis has been proven to stop the visual deterioration caused by AMD, and in some cases may even lead to a slight improvement. Many doctors think the same is true for Avastin.

Avastin, the anti-cancer drug already widely used off-label by physicians to treat the wet form of age-related macular degeneration, is as effective as Lucentis, the gold standard for treatment of ...

NEI launched CATT in 2008 to compare Lucentis and Avastin for treatment of wet AMD. The study has now reported results for 1,185 patients treated at 43 clinical centers in the United States.

Combined Part B expenditures for Lucentis and Avastin approached $2 billion in 2010. To understand when and why physicians opt for Avastin over Lucentis for the treatment of wet AMD, ...

A study published in Health Affairs by researchers from the University of Michigan’s Health Management and Policy and Ophthalmology and Visual Sciences departments say research shows that Avastin and ...

Lucentis and Avastin were both developed by Genentech, a division of pharmaceutical giant Roche. A little over three years ago, the National Eye Institute announced that 47 vision research ...

But Lucentis costs as much as $2,000 per dose, so many physicians have begun substituting the similar anti-cancer drug Avastin (bevacizumab), which costs less than $150 per dose.

Two popular drugs used to treat age-related macular degeneration (AMD) appear to be equally effective in improving vision, according to a new study. The difference? One costs $2,000 per dose, but ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

I’m a doctor with a miracle drug. Three of them, in fact. Their names are Avastin, Lucentis and Eylea. I use them to treat the No. 1 cause of blindness in Americans over 65: wet age-related ...

In 2010, the combined cost of using Avastin and Lucentis to treat eye disorders was around $2 billion — or about one-sixth of the entire Medicare Part B drug budget.

LONDON – A head-to-head study funded by the UK Department of Health has found Avastin and Lucentis are equally effective and safe in treating wet age-related macular degeneration (AMD), and that using ...